More tools:Markets·Screener·Research·Chat

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Financial Statements

Madrigal Pharmaceuticals, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SNKQ42
XNAS · usd
534.16▼ 6.92 (-1.28%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close541.08
Day's Range526.67 – 540.00
52-Week Range393.61 – 615.00
Volume198.8K
Avg Volume324.4K
Share Statistics
Shares Outstanding
Employees915
ExchangeXNAS
Listed2007-02-06
Share count as of July 27, 2026
Loading Income Statement…
Key questions about Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
What is Madrigal Pharmaceuticals, Inc. Common Stock's Market Cap?
Madrigal Pharmaceuticals, Inc. Common Stock's Market Cap is $12.3B, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Madrigal Pharmaceuticals, Inc. Common Stock's Enterprise Value is $12.4B, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's Price / Sales?
Madrigal Pharmaceuticals, Inc. Common Stock's Price / Sales is 9.6×, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's EV / Revenue?
Madrigal Pharmaceuticals, Inc. Common Stock's EV / Revenue is 9.6×, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
Madrigal Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Madrigal Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Madrigal Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$325.1M, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's EBITDA?
Madrigal Pharmaceuticals, Inc. Common Stock's EBITDA is -$321.1M, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Madrigal Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -14.07, based on as-reported figures from SEC (XBRL) filings.
What is Madrigal Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
Madrigal Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -25.0%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Product revenue, net
YoY growth+71.2%+126.8%+210.8%+362.0%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
% of revenue115.5%129.8%118.6%139.7%
Loss from operations
% of revenue-15.5%-29.8%-18.6%-39.7%
Interest income
Interest expense
Other expense, net
Net loss
% of revenue-15.9%-30.3%-18.2%-39.8%
Basic net loss per common, Series A preferred, and Series B preferred share (in dollars per share)
Diluted net loss per common, Series A preferred, and Series B preferred share (in dollars per share)